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patients (15.2%) of 2984 treated, and third line 529 patients (33%) of 1603 treated.We
found similar results using the IMPACT database: 2,256 (7.8%) CRC patients had a
test ordered for K-ras between 2005 and 2010. K-ras testing increased with line of
therapy: first line 244 patients (7.8%), second line 510 (14.6%), and third line 650
patients (33.1%). EMR lab results from stage IV disease (n349) consisted of 15%
mutated type, 60% unknown and 25% wild type. For confirmed test results wild
type represented 62.5% and mutated type 37.5%. CONCLUSIONS: Over the last six
years, use of K-ras testing has increased in use in patients with CRC. The increase
has occurred in later lines of therapy. The timing occurring late in therapy may
limit the use of agents specific for this test.
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OBJECTIVES: The aim of this study is to evaluate the accuracy of non-invasive
diagnosis methods for ischemic heart disease in patients with chest pain.
METHODS:A retrospective cohort study was performed on new patients who have
not received any diagnosis of ischemic heart disease or treatment before among
those over 30 years of agewho visited the cardiology outpatient clinic between 2006
to 2008 in a single medical institution. Among non-invasive diagnostic methods,
stress ECG(sECG), myocardial SPECT, and CT coronary angiography(CTCA) were
included in our study. Since coronary angiography(CAG) was not performed in all
patients, the comparison of test accuracy was calculated by correcting referral bias
to CAGdepending onnon-invasive test results based on the Bayes Theorem, and by
reflecting the 1-year follow-up results. RESULTS: Among 4743 patients selected,
2485 patients received more than one of the following non-invasive tests: sECG,
SPECT, and CTCA for differential diagnosis. sECG was performed in 853 pa-
tients(34.3%), SPECT in 997 patients(40.1%), andCTCA in 635 patients(25.6%). A total
of 592 patients(23.8%) received CAG among the 2485 patients. Test indices adjusted
for referral bias using the 2 methods were a sensitivity of 49% or 80% in sECG, 46%
or 75% in SPECT and 57% or 88% in CTCA, a specificity of 65% or 62%, 81% or 78% in
SPECT and 96%or 81% inCTCA. A likelihood ratio for a positive testwere 1.39 or 2.08
in sECG, 2.47 or 3.38 in SPECT and 14.14 or 4.65 in CTCA, and a likelihood ratio for a
negative test were 0.79 or 0.33 in sECG, 0.66 or 0.32 in SPECT and 0.45 or 0.14 in
CTCA. CONCLUSIONS: In conclusion, the accuracy of diagnosing ischemic heart
disease was the highest in CTCA, followed by myocardial SPECT and sECG by cor-
recting referral bias to CAG.
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OBJECTIVES: To evaluate long-term clinical outcomes of elderly Medicare benefi-
ciaries who underwent non-emergent coronary stenting.METHODS: This popula-
tion-based prospective study analyzed patients in a large nationally representative
administrative claims database. The sample consisted of Medicare patients aged
65 who underwent a non-emergent coronary stent between 2006 and 2010. Pa-
tients were identified by existence of a hospital claim for a bare metal stent (ICD-
9-CM procedure code 36.06) or drug-eluting stent (ICD-9-CM procedure code 36.07
or codes 36.06 and 36.07). Eligible patients were followed one to five years after
stenting to assess risk of revascularization, myocardial infarction (MI), coronary
artery bypass surgery (CABG), and death. Long-term clinical outcomes were based
on HEDIS 2010 technical specifications. RESULTS: The study population included
26,023 patients that underwent a coronary bare-metal stent (female  40.15%, age
 75.38 ( 6.66), history ofMI 7.97%, history of CABG 1.01%) and 74,448 patients
that underwent a coronary drug-eluting stent (female  40.17%, age  73.78 (
6.19), history of MI  7.39%, history of CABG  1.27%). Patients with drug-eluting
stents had a lower risk of revascularization (29.57% vs. 31.65%, p  0.001), CABG
(1.40% vs. 2.57%, p  0.001), and mortality (4.96% vs. 9.25%, p  0.001) within one
year follow-up after stenting. There was no significant difference in the risk for MI
within one to four years follow-up (3.35% vs. 3.29%, p  0.05), but there was a
significant difference in risk of MI at five year follow-up (7.33% vs. 3.36%, p 0.001).
Mortality rates significantly increased over time in patientswith a bare-metal stent
whilemortality rates for thosewith a drug-eluting stent remained relatively stable.
CONCLUSIONS: The use of drug-eluting stents was significantly correlated with a
decline in long-term risk of revascularization, CABG,MI anddeath in comparison to
bare-metal stents.
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OBJECTIVES: About 10-15% of individuals with diabetes mellitus develop foot ul-
cers which precede 85% of amputations. Increased oxygen exposure, through the
use of hyperbaric oxygen therapy (HBOT), has been suggested to encourage ulcer
healing thus reducing the risk of amputation. The objective of this systematic
review is to evaluate the efficacy of systemic HBOT for non-healing ulcers of the
lower limb in diabetes patients. METHODS: A systematic search of the published
literature was conducted using controlled and keyword terms focusing on “HBOT”
and “lower limb diabetic ulcers”. Databases searched included Medline, EMBASE,
CINAHL, PubMed, Wiley’s Cochrane Library, and Biosis. Randomized controlled
trials (RCTs) and observational studies were included and no year or language
limits were employed. Two reviewers screened the articles. Pooled estimates of
outcomes were calculated using Review Manager when appropriate. RESULTS: Of
the 543 citations identified, 152 articles underwent full-text review. Data was ab-
stracted from 27 publications (7 RCTs, 9 comparative observational, and 11 non-
comparative observational studies). Primary outcomes of rates of amputation (ma-
jor or minor) and wound healing were identified. Relative risk (RR) estimates from
RCTs in the pooled analysis reflect a significant reduction inmajor amputation (RR
 0.32, 95% CI 0.11 to 0.91) with HBOT. For the proportion of unhealed wounds,
HBOT is also favoured (RR  0.45, 95% CI 0.32 to 0.64). CONCLUSIONS: The limited
RCT evidence surrounding the efficacy of HBOT favours the use of HBOT for non-
healingwounds of the lower limb for diabetes patients. Rigorous clinical trials with
larger sample sizes, however, need to be conducted to more conclusively establish
the benefits and harms of treating diabetic lower limb ulcers with HBOT.
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OBJECTIVES: The increasing use of both PET scan and surgical lymph node evalu-
ation in the cervical cancer (CC) treatment has led to a clinical debate. The objective
of this study is to provide a cost analysis of routine PET imaging in the work-up of
CC. METHODS: A decision-tree model was designed to compare pre-treatment
evaluation including PET-scan versus FIGO staging. Primary outcome was correct
primary treatment (CPT) due to the use of PET or FIGO. Cost effectiveness ratios
were calculated and results were expressed in terms of incremental cost effective-
ness ratio (ICER). The model used the SEER 2011 database (n12,200), for number,
incidence, and stage distribution of CC. Medicare reimbursement rates were used
for costs. Lymph nodemetastasis rates for each stage, and performance character-
istics of PET were abstracted from published data. Cited values were used and
varied over for sensitivity analysis. RESULTS: The addition of PET-scan to FIGO
clinical staging for IA1 CC resulted in 6(0.5%) more CPTs than FIGO staging at
baseline. In stage IA2, 75(6%) more CPT were performed and 187(14%) in stage IB1,
and an additional 322(24%) in IB2. In stage IIA, PET-scan resulted in an additional
50(3%) CPT (ICER$75,575), compared to 234(12%) CPT (ICER$61,509) in stage IIB,
and 333(26%) additional CPT in stage IIIA, (ICER $48,293). In stage IIIB and IVA the
addition of PET resulted in 240(19%) more CPT, and 41(8%) additional CPT in stage
IVA (ICER$52,791 vs.$71,810). Outcomes were sensitive to changes in prevalence
and PET performance in the sensitivity analysis.CONCLUSIONS:Routine pre-treat-
ment PET-scan may be cost effective for stage IA2-IB2 CC. The inclusion of PET-
scan in the pre-treatment evaluation of stage I CC increased the number of CPT
with an elevated ICER. The findings of this model need to be validated in the
clinical-setting to generate knowledge on best resources’ allocation.
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OBJECTIVES: Low dose computed tomography (CT) is the current recommended
lung cancer screening modality for selected high risk population. The role of bio-
markers is not clear. The objective of our study is to investigate the role of biomark-
ers in lung cancer screening via a systematic review andmeta-analysis.METHODS:
A systematic review is performed by reviewing primary studies focusing on bio-
markers for lung cancer screening using the following keywords (lung cancer) AND
((screen*) OR (diagnosis) OR (diagnostic) OR (prediagnostic) OR (detection) OR (pre-
dict*) OR (development)) AND ((biomarker) OR (blood) OR (serum) OR (sera) OR
(plasma) OR (antibodies) OR (urin*) OR (sputum) OR (exhale*) OR (volatile) OR (epi-
thelium)OR (epithelial) OR (bronchial) OR (airway)) in the title/abstract in Pubmed®
on December 31, 2011. We further limited our search to clinical trials, meta-anal-
ysis, or randomized controlled trials published for the past 5 years in English. Two
independent reviewers identified studies compatible for selection criteria and data
extraction after consensuswas reached.Manual searching for relevant studieswas
also performed from relevant studies. A randomeffectmodel was used to calculate
the pooled diagnostic performance of biomarker screening. RESULTS: Among the
identified studies (n172), three studies were included. In total, 1932 participants
received various kinds of biomarkers screening. By using these biomarkers to dif-
ferentiate cancer from non-cancer, the estimated pooled sensitivity and specificity
with 95% confidence interval was 40% (24%  57%) and 96% (94%  97%)
respectively. CONCLUSIONS: The diagnostic performance of biomarkers for lung
cancer screening is fair based on very limited data as found in this systematic
review. The role of biomarkers in lung cancer screening deserves further studies.
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